Restoring Metabolic Balance.

Transforming Lives.

Developing medicines to reverse the course of serious metabolic diseases.

NASH: A Life-Threatening Liver Disease

NASH (non-alcoholic steatohepatitis) is rapidly emerging as the leading cause of liver disease around the world, driven by the growing global epidemic of obesity and diabetes. NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver cell (hepatocyte) damage, liver inflammation, and fibrosis that can progress to cirrhosis, liver failure, cancer and death.

MORE ABOUT NASH
Abstract Illustration of Liver
Illustration of AKR-001

Our Lead Candidate: AKR-001

AKR-001 is an investigational treatment for NASH being evaluated in a Phase 2 clinical trial. AKR-001 is engineered to harness the inherent benefits of a naturally-occurring hormone called FGF21 with once-weekly subcutaneous dosing. AKR-001 addresses both the underlying metabolic drivers of NASH and the downstream consequences of inflammation and fibrosis.

More About AKR-001

Delivering Transformational Therapies for Patients

Akero Therapeutics is a clinical-stage company led by a team of industry veterans dedicated to developing transformational therapies for serious metabolic diseases. Our initial focus is NASH, a serious and rapidly-growing condition for which there is no approved treatment.

More About Akero

In the News

January 13, 2020

Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

Read More

Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

Read More

December 16, 2019

AKERO THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2A STUDY IN NASH

December 16, 2019 SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that it has completed enrollment in the Phase 2a BALANCED study of AKR-001, a novel FGF21 analog, for the treatment of NASH. “We believe […]

Read More

November 13, 2019

AKERO THERAPEUTICS TO PRESENT AT THE JEFFERIES 2019 LONDON HEALTHCARE CONFERENCE

November 13, 2019 SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 8:00 a.m. GMT on Wednesday, November 20, 2019. A […]

Read More

November 12, 2019

AKERO THERAPEUTICS REPORTS RECENT HIGHLIGHTS AND THIRD QUARTER 2019 FINANCIAL RESULTS

November 12, 2019 SAN FRANCISCO, Nov. 12, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today reported third quarter 2019 financial results for the period ending September 30, 2019. “The third quarter of 2019 was a period of continued clinical and manufacturing progress […]

Read More

November 11, 2019

Akero Chief Development Officer Kitty Yale Named to 2019 Fierce Pharma “Fiercest Women in Life Sciences”

November 11, 2019 Akero Therapeutics is thrilled to announce that its chief development officer Kitty Yale has been recognized by FiercePharma as one of 2019’s “Fiercest Women in Life Sciences.” Kitty joined Akero from Gilead Sciences, Inc. where she led global clinical operations and management of the company’s oncology, HIV, inflammation and liver disease trials. […]

Read More

Read More News

© 2019 Akero Therapeutics, Inc. All rights reserved. Terms of Use.